Cellular heterogeneity and an immunosuppressive tumour microenvironment are
independent yet synergistic drivers of tumour progression and underlie therapeutic …

Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and
disease progression. Technological and computational advances have enabled us to …

Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …

Background Although immune checkpoint inhibitor (ICI) is regarded as a breakthrough in
cancer therapy, only a limited fraction of patients benefit from it. Cancer stemness can be the …

Acute exposure of cancer cells to high concentrations of type I interferon (IFN-I) drives
growth arrest and apoptosis, whereas chronic exposure to low concentrations provides …

Cancer stem cells (CSCs) are self-renewing cells that facilitate tumor initiation, promote
metastasis, and enhance cancer therapy resistance. Transcriptomic analyses across many …

Background T cells form the major component of anti-tumor immunity. A deeper
understanding of T cell exhaustion (TEX) heterogeneity within the tumor microenvironment …

Prostate cancer is characterized by a high degree of heterogeneity, which poses a major
challenge to precision therapy and drug development. In this review, we discuss how …

Tumor-infiltrating immune cells play a key role against cancer. However, malignant cells are
able to evade the immune response and establish a very complex balance in which different …

Hepatocellular carcinoma (HCC) represents a paradigm of the relation between tumor
microenvironment (TME) and tumor development. Here, we generate a single-cell atlas of …